Mr. Read began his career at Pfizer in 1978 and was named CEO in 2010 and Chairman of the Pfizer Board of Directors in 2011. During Mr. Read’s tenure as CEO, Pfizer generated a total shareholder return of 250%, achieved 32 FDA approvals for new medicines, invested significantly in research and development, and completed several transformational transactions to help strengthen Pfizer’s pipeline. Previously, Mr. Read served as Senior Vice President and Group President of Pfizer’s Worldwide Biopharmaceutical Businesses, overseeing five global business units: Primary Care, Specialty Care, Oncology, Established Products and Emerging Markets. Prior to this, he held positions in several of the company’s largest, fastest growing operations, including Chief Financial Officer, Pfizer Mexico, and Country Manager, Pfizer Brazil. Mr. Read continues to serve on the board of directors of Kimberly‐Clark and Viatris and is Chairman of DXC. He also serves as a Carlyle Operating Executive, focused on the healthcare sector

Mr. Read earned his B.S. in chemical engineering from London University Imperial College and subsequently became a Charted Accountant of England and Wales.
 

 

Back